Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
作者： Rachel Schiff , Suleiman A. Massarweh , Jiang Shou , Lavina Bharwani , Grazia Arpino
DOI: 10.1007/S00280-005-0108-2
关键词:
摘要: Estrogen receptor (ER), mediating estrogen-signaling stimuli, is a dominant regulator and a key therapeutic target in breast cancer etiology and progression. Endocrine therapy …
springer.com
core.ac.uk
elsevier.com
sci-hub.se 参考文章(99)
健二郎 青儀, What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及ぼす効果を示した論文:無作為化比較試験のメタアナリシス Mebio oncology. ,vol. 3, pp. 94- 98 ,(2006)
Malcolm G. Parker, Nuclear hormone receptors : molecular mechanisms, cellular functions, clinical abnormalities Academic Press. ,(1991)
P. Le Goff, M.M. Montano, D.J. Schodin, B.S. Katzenellenbogen, Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. Journal of Biological Chemistry. ,vol. 269, pp. 4458- 4466 ,(1994) , 10.1016/S0021-9258(17)41801-1
Santo V. Nicosia, June E. Paciga, Richard I. Feldman, Mei Sun, Jin Q. Cheng, Domenico Coppola, Sue A. Shelley, You Yong Lu, Zeng-qiang Yuan, Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Research. ,vol. 61, pp. 5985- 5991 ,(2001)
Carlos L. Arteaga, James T. Forbes, Paul I. Pisacane, Jean F. Simpson, Hirokazu Kurokawa, Mark X. Sliwkowski, Anne E. G. Lenferink, Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Research. ,vol. 60, pp. 5887- 5894 ,(2000)
Steve Ebbs, Mitch Dowsett, Irene Boeddinghaus, Catherine Harper-Wynne, Ian Smith, Mike Dixon, Gerald Gui, Janine Salter, Margaret Hills, Nigel Sacks, HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer Cancer Research. ,vol. 61, pp. 8452- 8458 ,(2001)
Gemma A. Figtree, Carolyn M. Webb, Peter Collins, Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism. Journal of Pharmacology and Experimental Therapeutics. ,vol. 295, pp. 519- 523 ,(2000)
C. Kent Osborne, Hong (Holly) Zhao, Suzanne A. W. Fuqua, Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use Journal of Clinical Oncology. ,vol. 18, pp. 3172- 3186 ,(2000) , 10.1200/JCO.2000.18.17.3172
Early Breast Cancer Trialists' Collaborative Group, None, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials The Lancet. ,vol. 365, pp. 1687- 1717 ,(2005) , 10.1016/S0140-6736(05)66544-0
Gerald E Stoica, Thomas F Franke, Anton Wellstein, Elisha Morgan, Frank Czubayko, Heinz-Joachim List, Ronald Reiter, Mary Beth Martin, Adriana Stoica, Heregulin-β1 regulates the estrogen receptor-α gene expression and activity via the ErbB2/PI 3-K/akt pathway Oncogene. ,vol. 22, pp. 2073- 2087 ,(2003) , 10.1038/SJ.ONC.1206311